# Safety and Efficacy of Mitapivat Sulfate in Adult Patients With Erythrocyte Membranopathies

> **NCT05935202** · PHASE2 · NOT_YET_RECRUITING · sponsor: **EuroBloodNet Association** · enrollment: 25 (estimated)

## Conditions studied

- Hereditary Red Blood Cell Disorder (Disorder)

## Interventions

- **DRUG:** Mitapivat sulfate

## Key facts

- **NCT ID:** NCT05935202
- **Lead sponsor:** EuroBloodNet Association
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-12-21
- **Primary completion:** 2025-07-15
- **Final completion:** 2026-12-15
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2023-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05935202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05935202, "Safety and Efficacy of Mitapivat Sulfate in Adult Patients With Erythrocyte Membranopathies". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05935202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*